- Page 1 and 2:
CURRENT INTELLIGENCE BULLETIN 65Occ
- Page 3 and 4:
Current Intelligence Bulletin 65Occ
- Page 5 and 6:
ForewordThe Occupational Safety and
- Page 7 and 8:
Executive SummaryOverviewCarbon nan
- Page 9 and 10:
2009; Pauluhn 2010a; Porter et al.
- Page 11 and 12:
neurogenic sig nals from sensory ir
- Page 13 and 14:
possible. Until the results from an
- Page 15 and 16:
••Follow exposure and hazard as
- Page 17 and 18:
Periodic Evaluations••Evaluatio
- Page 19 and 20:
ContentsForeword ..................
- Page 21 and 22:
A.3.2 Comparison of Short-term and
- Page 23 and 24:
ESPFeFMPSFPSSgGMGSDHCLHECHEPAhrISOI
- Page 25 and 26:
AcknowledgementsThis Current Intell
- Page 27 and 28:
1 IntroductionMany nanomaterial-bas
- Page 29:
2 Potential for ExposureThe novel a
- Page 32 and 33:
CNMs, with MWCNT agglomerates obser
- Page 34 and 35:
composite materials with local exha
- Page 36 and 37:
information on air contaminants. Sa
- Page 39 and 40:
3 Evidence for Potential Adverse He
- Page 41 and 42:
decreasing agglomerate size increas
- Page 43 and 44:
examined up to 60 days post-exposur
- Page 45 and 46:
3.3 SWCNT and MWCNTIntraperitoneal
- Page 47 and 48:
The same potency sequence was obser
- Page 49 and 50:
Table 3-3. Findings from published
- Page 51 and 52:
Table 3-5. Findings from published
- Page 53 and 54:
Table 3-6. Findings from published
- Page 55 and 56:
Table 3-7 (Continued). Findings fro
- Page 57:
Table 3-8. Findings from published
- Page 60 and 61:
length, respectively) [Muller et al
- Page 63 and 64:
5 CNT Risk Assessment and Recommend
- Page 65 and 66:
A-6). Risk estimates derived from o
- Page 67 and 68:
Table 5-4. Factors, assumptions, an
- Page 69 and 70:
and analytical methods. NIOSH is re
- Page 71 and 72:
Table 5-5. Recommended occupational
- Page 73 and 74:
deficits in animals or clinically s
- Page 75:
(3) Rat lung dose estimationIn the
- Page 78 and 79:
tasks where worker exposures exceed
- Page 80 and 81:
As part of the evaluation of worker
- Page 82 and 83:
Table 6-1. EC LODs and LOQs for 25-
- Page 84 and 85:
6.2 Engineering ControlsOne of the
- Page 86 and 87:
Table 6-6 (Continued). Examples of
- Page 88 and 89:
Table 6-7 (Continued). Engineering
- Page 90 and 91:
exposure estimates for SWCNT on ind
- Page 92 and 93:
Table 6-8. Respiratory protection f
- Page 94 and 95:
••Workers in areas or in jobs w
- Page 97 and 98:
7 Research NeedsAdditional data and
- Page 99 and 100:
ReferencesACGIH [1984]. Particle si
- Page 101 and 102:
Bolton RE, Vincent HJ, Jones AD, Ad
- Page 103 and 104:
eport issued on July 22, 2011. NEDO
- Page 105 and 106:
Kobayashi N, Naya M, Mizuno K, Yama
- Page 107 and 108:
Methner M, Hodson L, Geraci C [2010
- Page 109 and 110:
Human Services, Centers for Disease
- Page 111 and 112:
Piegorsch WW, Bailer AF [2005]. Qua
- Page 113 and 114:
AD, Baron PA [2003]. Exposure to ca
- Page 115:
Varga C, Szendi K [2010]. Carbon na
- Page 119 and 120:
ContentsA.1 Introduction ..........
- Page 121 and 122:
A.1 IntroductionThe increasing prod
- Page 123 and 124: provide an informal check on the es
- Page 125 and 126: these same dose groups; this effect
- Page 127 and 128: Table A-1. Rodent study information
- Page 129 and 130: the deposited (no clearance) and th
- Page 131 and 132: The other BMDS models failed to con
- Page 133 and 134: Figure A-2. Benchmark dose model (m
- Page 135 and 136: Figure A-3 (continued). Benchmark d
- Page 137 and 138: Table A-3. Benchmark dose estimates
- Page 139 and 140: Table A-5. Benchmark dose estimates
- Page 141 and 142: histopathology grade 2 or higher lu
- Page 143 and 144: Table A-8. Working lifetime percent
- Page 145 and 146: developing early-stage adverse lung
- Page 147 and 148: Figure A-4. Dose-response relations
- Page 149 and 150: cell surface area). However, the wo
- Page 151 and 152: purified or unpurified (with differ
- Page 153 and 154: Table A-9. Comparison of rat or hum
- Page 155 and 156: A.6.1.3 Pulmonary Ventilation RateT
- Page 157 and 158: used as the effect levels in evalua
- Page 159 and 160: the DF estimate, although a larger
- Page 161 and 162: or overloading, of particle clearan
- Page 163 and 164: Table A-13. Human-equivalent retain
- Page 165 and 166: A.7.1 Particle CharacteristicsBoth
- Page 167 and 168: and density. The following MMAD and
- Page 169: Table A-15. CNT lung dose normalize
- Page 172 and 173: B.1 Key Terms Related toMedical Sur
- Page 176 and 177: C.1 BackgroundNIOSH Method 5040 is
- Page 178 and 179: the thermal-optical instrument was
- Page 180 and 181: sampler type, and as expected, diff
- Page 182: Table 1. NIOSH 5040 precision for a